AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8874117
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with 9 ml of 3 ml albumin, 3 ml glucose, and 3 mEq of sodium bicarbonate (group B, n = 24)
Trial: 8874117
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with 4.5 ml albumin and 4.5 ml glucose (group C, n = 14)
Trial: 31581591
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement enriched with leucine
Trial: 22385885
Drug: 10mg fluvastatin/20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg fluvastatin/20mg valsartan daily for 30 days
Trial: 3394886
Drug: Imipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine treatment for 6 weeks
Trial: 16826400
Drug: Psilocybin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (30 mg/70 kg)
Trial: 16826400
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (40 mg/70 kg)
Trial: 14655885
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) - 3 sessions of 3000 shock waves/session at 0.2 mJ/mm2, weekly intervals
Trial: 14655885
Drug: Conventional conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional conservative treatment (iontophoresis with diclofenac and oral NSAID) for 12 weeks followed by ESWT protocol
Trial: 11035668
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 2,000 microg via metered‐dose inhaler for 5 consecutive days
Trial: 30203681
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal rings with 300 µg 17β-estradiol and 75-125 µg/day of etonogestrel (ENG)
Trial: 30203681
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal rings with 300 µg 17β-estradiol and 500-900 µg/day of nomegestrol acetate (NOMAC)
Trial: 30203681
Drug: ENG-E2 125/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENG-E2 125/300 µg/day group
Trial: 30203681
Drug: NuvaRing (ENG/ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuvaRing (ENG/ethinylestradiol 120/15 µg)
Trial: 24874006
Drug: Web‐based Solution‐Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web‐based Solution‐Focused Brief Therapy (SFBT) intervention (n=131)
Trial: 23327035
Drug: Dexmedetomidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (Group D) - loading dose of 1 microg/kg IV over ten minutes, followed by continuous infusion at 0.5 microg/kg/hr throughout surgery
Trial: 23327035
Drug: Saline (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (Group S) - same volume as dexmedetomidine infusion
Trial: 20573787
Drug: 35 micro
RxNorm normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 micro g Se as l-selenomethionine
Trial: 20573787
Drug: 21 micro
RxNorm normalized name: Ipratropium bromide 21 microgram/actuation nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 micro g Se as l-selenomethionine
Trial: 20573787
Drug: 0 micro
RxNorm normalized name: EM 2400 Micro Volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 micro g Se (placebo)
Trial: 18043579
Drug: Dose-intensive epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensive epirubicin and cyclophosphamide with filgrastim and progenitor cell support (DI-EC)
Trial: 18043579
Drug: Standard-dose anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose anthracycline-based chemotherapy (SD-CT)
Trial: 18506618
Drug: Integrated Assertive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Assertive Community Treatment (IACT)
Trial: 16897413
Drug: Assertive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive Community Treatment only (ACTO)
Trial: 12827120
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream with heat for 20 minutes
Trial: 12827120
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream for 60 minutes without heat
Trial: 1893291
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human calcitonin 0.25 mg
Trial: 1893291
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human calcitonin 0.125 mg
Trial: 6380896
Drug: Nitrogen mustard
RxNorm normalized name: Nitrogen mustard
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrogen mustard (0.1 mg/kg body weight) administered in 3 intravenous bolus injections over 3-5 weeks
Trial: 21993365
Drug: Medication Event
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication Event Monitoring System (MEMS) and pill count
Trial: 21993365
Drug: Pill count
RxNorm normalized name: Pill Counting Tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill count alone (control group)
Trial: 20859153
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion below the fascia using ropivacaine and ketoprofene
Trial: 20859153
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion above the fascia using ropivacaine and ketoprofene
Trial: 16160802
Drug: Strict metabolic
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict metabolic control with insulin administration (fasting glucose levels to 90 mg/dl and 130 mg/dl postprandially)
Trial: 9002334
Drug: Mega-dose capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mega-dose capsule distribution (100,000 IU for 6-12 months; 200,000 IU for 1-5 years)
Trial: 1618248
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of quinine (500 mg)
Trial: 1618248
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of quinine (500 mg)
Trial: 1618248
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intravenous administration of quinine (500 mg)
Trial: 6204486
Drug: Topical clobetasol-17-propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol-17-propionate
Trial: 31227432
Drug: Abiraterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg daily) + Dasatinib (100 mg daily)
Trial: 31227432
Drug: Abiraterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg daily)
Trial: 28282396
Drug: Malaria vaccine
RxNorm normalized name: malaria vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria vaccine (FMP2.1/AS02A)
Trial: 23658438
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg daily)
Trial: 21542741
Drug: Leukotriene-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Leukotriene-receptor antagonist (LTRA)
Trial: 30823952
Drug: Inhaled glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid
Trial: 21542741
Drug: Long-acting beta(2)-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta(2)-agonist (LABA)
Trial: 19542792
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 or 120 mg/d
Trial: 12527545
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance interpersonal psychotherapy (IPT)
Trial: 12527545
Drug: Monthly clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly clinical management and pill placebo
Trial: 12527545
Drug: Supportive clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive clinical management and pill placebo
Trial: 11755835
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% twice daily
Trial: 8291420
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections of hyaluronan (placebo control: saline injections)
Trial: 8291420
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole treatment
Trial: 29457986
Drug: Oro-motor stimulation
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oro-motor stimulation for 5 min twice a day
Trial: 24941841
Drug: Transcutaneous acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous acupoint electrical stimulation (TAES) combined with general intravenous anesthesia
Trial: 24941841
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (control group)
Trial: 20843301
Drug: Assertive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Assertive intervention based on a modified version of the international model of assertive community treatment
Trial: 16155276
Drug: +ISO (58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +ISO (58 g protein powder/d containing 83 mg isoflavones/d)
Trial: 16155276
Drug: -ISO (ethanol-extracted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -ISO (ethanol-extracted soy-protein powder containing 3 mg isoflavones)
Trial: 28912936
Drug: QSNYL-FEYL combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QSNYL-FEYL combination
Trial: 27488365
Drug: Morning ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning ingestion of warfarin
Trial: 27488365
Drug: Evening ingestion
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening ingestion of warfarin (control)
Trial: 25151492
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (EX) - 10min bouts of thrice‐weekly jumping plus capoeira
Trial: 8314201
Drug: Bio‐Tropin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 8.00‐10.00 h (M group)
Trial: 8314201
Drug: Bio‐Tropin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 14.00‐16.00 h (AN group)
Trial: 8314201
Drug: Bio‐Tropin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 19.00‐21.00 h (NT group)
Trial: 3302121
Drug: Budipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine (60 mg daily)
Trial: 11883307
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (for vaginal hysterectomy)
Trial: 27299457
Drug: SC peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC peginterferon β‐1a 125 mcg every-2-weeks
Trial: 27299457
Drug: SC peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC peginterferon β‐1a 125 mcg every-4-weeks
Trial: 22323410
Drug: Plasma 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma 25-hydroxyvitamin D (highest tertile, median concentration 30.1 ng/mL)
Trial: 17367217
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg + Amoxicillin 1g + Metronidazole 500 mg + Bismuth subcitrate 240 mg twice daily for two weeks (Group A)
Trial: 17367217
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg + Amoxicillin 1g + Furazolidone 200 mg twice daily + Bismuth subcitrate 240 mg twice daily for two weeks (Group B)
Trial: 17367217
Drug: Furazolidone regimen
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone regimen for the first week followed by Omeprazole + Amoxicillin + Metronidazole + Bismuth subcitrate for the second week (Group C)
Trial: 12188390
Drug: 1,400 mg
RxNorm normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,400 mg BID of saquinavir soft gel with zidovudine and lamivudine
Trial: 12188390
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg TID of saquinavir soft gel with zidovudine and lamivudine
Trial: 7586356
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg BID
Trial: 7586356
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg TID
Trial: 2177889
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2 puffs à 2 mg)
Trial: 7447172
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic treatment
Trial: 31522845
Drug: Ranibizumab 0·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0·2 mg
Trial: 31522845
Drug: Ranibizumab 0·1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0·1 mg
Trial: 31522845
Drug: Ranibizumab 0·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0·2 mg vs Laser therapy
Trial: 31522845
Drug: Ranibizumab 0·1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0·1 mg vs Laser therapy
Trial: 31522845
Drug: Ranibizumab 0·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0·2 mg vs Ranibizumab 0·1 mg
Trial: 26554707
Drug: Non-optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-optimal treatment (CT or IPT)
Trial: 20499362
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment in postmenopausal women for 4 weeks
Trial: 20499362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no estrogen treatment) in postmenopausal women (n = 18)
Trial: 19302912
Drug: Naproxen sodium/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen sodium/paracetamol 375/300 mg per 15 mL suspension
Trial: 19302912
Drug: Naproxen sodium/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen sodium/paracetamol 275/300 mg tablet
Trial: 15114697
Drug: S-1 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administered twice daily at 80, 100 or 120 mg/body/day for 28 days followed by 14 days of rest
Trial: 11263760
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic drugs for Alzheimer's disease
Trial: 9713009
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Trial: 9713009
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Trial: 2928433
Drug: Diazepam (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.14 mg/kg)
Trial: 31734103
Drug: Cenobamate 200
RxNorm normalized name: cenobamate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 200 mg
Trial: 30131425
Drug: High dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysate magnesium (2.0 mEq/L) for 28 days
Trial: 30131425
Drug: Standard dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysate magnesium (1.0 mEq/L)
Trial: 24264551
Drug: Gabapentin 15
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 15 mg.kg‐1 dissolved in 10 ml of saline orally 30 min. before induction of anesthesia
Trial: 24264551
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of saline (Control)
Trial: 19108793
Drug: OXN FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN FDC (10/5 mg, 20/10 mg, 40/20 mg)
Trial: 19108793
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR 40 mg + Naloxone PR 20 mg
Trial: 19108793
Drug: OXN FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN FDC 40/20 mg
Trial: 19108793
Drug: Naloxone PR
RxNorm normalized name: naloxone Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone PR tablet 20 mg
Trial: 19108793
Drug: OXN, Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN, Oxycodone PR, Naloxone PR
Trial: 10781448
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% alone, 1.0 mL/kg
Trial: 8227450
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg meclofenamate sodium bid
Trial: 8227450
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg meclofenamate sodium bid
Trial: 30998396
Drug: Genotype-guided antiplatelet
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided antiplatelet therapy
Trial: 28069009
Drug: Nocturnal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal oxygen therapy for 3 years
Trial: 23712446
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg betamethasone intravenously
Trial: 10959510
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (ligation or stripping)
Trial: 19576645
Drug: High-dose concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose concurrent chemo-radiation followed by surgery
Trial: 12040670
Drug: Concurrent chemo-radiation
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiation
Trial: 10648315
Drug: Ephedrine 5
RxNorm normalized name: pseudoephedrine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 5 mg
Trial: 353121
Drug: Cyclandelate 1600
RxNorm normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate 1600 mg daily
Trial: 22561098
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy (mCIMT)
Trial: 18400976
Drug: EP HIV-1090
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP HIV-1090 (DNA vaccine)
Trial: 21838784
Drug: gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil 600 mg
Trial: 14640387
Drug: metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 850 mg
Trial: 8648205
Drug: hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatitis B vaccine (control)
Trial: 1465689
Drug: HCTZ‐A therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ‐A therapy (50 mg hydrochlorothiazide, 5 mg amiloride)
Trial: 1465689
Drug: Pindolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (15 mg) plus HCTZ‐A
Trial: 1465689
Drug: Nadolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (120 mg) plus HCTZ‐A